Huihui Zhang, Jing Yan, Xiaoyong Ren, Ying Sheng, Zhenghui Wang, Jianmin Liang, Yan Yan, Yangyang Jia, Zhihui Li, Jin Hou^*

Oncologie, Vol.24, No.4, pp. 707-716, 2022, DOI:10.32604/oncologie.2022.027023 - 31 December 2022

Abstract Objective: To assess the efficacy and toxicity of nimotuzumab combined with neoadjuvant or induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Patients received intravenous nimotuzumab (400 mg, weekly for 1–3 weeks) combined with chemotherapy (5-fluorouracil/paclitaxel/docetaxel + nedaplatin/cisplatin for 1–2 cycles), prior to definitive surgical resection, radiotherapy or other treatments. The primary endpoint was the objective response rate (ORR). The secondary endpoints were tumor downstaging, complete response rate (CRR), partial response rate (PRR), disease control rate (DCR), R0 resection rate, pathological complete response (pCR), larynx preservation rate, overall survival (OS), progression-free survival (PFS), and… More >

Wang Fangzheng^*†1, Jiang Chuner^‡1, Ye Zhiming^*†, Liu Tongxin^*†, Yan Fengqin^*†, Wang Lei^*†, Li Bin^*†, Hu Fujun^*†, Chen Ming^*†, Qin Weifeng^*†, Fu Zhenfu^*†

Oncology Research, Vol.26, No.2, pp. 277-287, 2018, DOI:10.3727/096504017X15079846743590

Abstract In this retrospective review of a single institution’s experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC) were studied. Between August 2008 and March 2014, 39 newly diagnosed patients with stages III–IV NPC were treated with IMRT, chemotherapy, and nimotuzumab. Twenty patients were diagnosed with stage III (51.3%), 14 with stage IVA (35.9%), and 5 with stage IVB (12.8%) disease. All patients received at least one cycle of cisplatin-based induction chemotherapy followed by IMRT and more… More >